tbuckley/cabot-search huggingface dataset:
Combination ibrutinib (Ibr) and venetoclax (Ven) for the treatment of mantle cell lymphoma (MCL): Primary endpoint assessment of the phase 2 AIM study.
Authors: Constantine Si Lun Tam, Andrew Warwick Roberts, Mary Ann Anderson, Sarah-Jane Dawson, Rodney J Hicks, Kate Burbury, Gillian Turner, Juliana Di Iulio, Mathias Bressel, David A. Westerman, Rishu Agarwal, Christiane Pott, Martin H. Dreyling, Mark A Dawson, John Francis Seymour
Journal: Journal of Clinical Oncology (2017)

7520 Background: Both ibr and ven have activity in relapsed/refractory (R/R) MCL, but complete remissions (CR) are attained in &lt;25% with either. We sought to determine the activity of the combination in an investigator-initiated, phase 2 study. Methods: Enrolment of 24 patients (pts) with R/R (n=23) or frontline (n=1) MCL completed in 09/16. Pts received 4 weeks of ibr (560mg/d), followed by introduction of ven (weekly ramp-up to target 400mg/d). The primary endpoint was CR rate at week 16, as assessed by PET/CT, BMAT, flow &amp; molecular MRD, and endoscopy (if baseline gut involvement). Response was calculated separately with and without knowledge of the PET result by IWG criteria (Cheson JCO 2007), in order to compare with published studies (ibr, 9% CR at wk16; ven, best CR rate 21%). Results: Median age of pts was 68 (range, 47-81) years. For the R/R pts (n=23), median lines of prior therapy was 2 (1-6), 48% were refractory to last treatment, and 30% had failed previous autologous SCT. As of data cutoff on Jan 11 2017, 18 pts remain on therapy, and 6 stopped treatment due to progressive disease (4), adverse event (1) or unrelated death (1). At week 16, ORR was 71% (63% CR) and 80% of complete responders were flow-cytometry negative in the marrow (sensitivity 10 -3 to 10 -4 ). Using CT without PET, the comparison responses were CR 42%, CRu 17%, PR 17% (ORR 78%). After a median follow-up of 8.3 (range 1.4-17.7) months, the 8-month estimates of PFS and OS months are 74% and 81%. Adverse events ≥20%, irrespective of attribution, were fatigue (71%), diarrhea (67%), nausea (50%), URTI (38%), gastro-esophageal reflux (33%), neutropenia (33%), cough (25%) and bruising (21%); with the exception of neutropenia (25% grade 3-4), these were predominantly grade 1-2 in severity. Tumour lysis syndrome occurred in 2 pts with high tumour burden, leading to revision of the protocol ven starting dose from 50mg, to 20mg/d. Conclusions: The combination of ibr and ven was tolerable and achieved CR rate of 63% at week 16 in pts with MCL. The efficacy results compare favorably with historical results, and warrant further phase III investigation. Clinical trial information: NCT02471391.
Brote de legionelosis entre los visitantes a una feria celebrada en Bélgica en 1999
Authors: K De Schrijver, E van Bouwel, L Mortelmans, P van Rossom, T De Beukelaer, C Vael, K Dirven, H Goossens, M Leven, O Ronveaux
Journal: Eurosurveillance (2000)

Noventa y tres casos de legionelosis (43 confirmados, 12 sospechosos y 38 posibles/clinicos) fueron identificados en un brote relacionado con una feria empresarial celebrada en Kapellen, Belgica, en noviembre de 1999. Cinco casos fallecieron. La investigacion epidemiologica mostro una relacion entre la duracion de la visita a la feria, la exposicion a determinadas zonas del recinto y la enfermedad. Las pruebas de reaccion en cadena de la polimerasa (polymerase chain reaction; -PCR-) mostraron contaminacion con legionella de un jacuzzi y una fuente.
In reference to higher serum testosterone is associated with increased risk of advanced hepatitis c-related liver disease in males
Authors: Marie Sinclair, Mathis Grossmann, Paul Gow, Peter Angus
Journal: Hepatology (2012)

We read with interest the article by White et al.,1 which concluded that serum total testosterone levels are associated with higher rates of fibrosis and inflammation in hepatitis C virus (HCV)-infected men. The hypothesis was raised that serum testosterone may be implicated in the pathogenesis of HCV-related advanced liver disease in males. Although this publication investigated the association of total serum testosterone, with fibrosis scores and inflammatory activity, sex hormone binding globulin levels and free testosterone levels were not determined. We therefore believe this raises some concerns regarding the validity of the reported association, given the known derangements seen in the sex hormones in patients with liver disease. In men, 60% of circulating testosterone is bound to sex hormone-binding globulin (SHBG), 38% is bound to albumin, and only 2% is unbound or free.2 SHBG levels are elevated in patients with cirrhosis due to increased hepatic production, but the pathogenesis of this remains unclear.3, 4 Rising levels of SHBG have been shown to correlate with severity of fibrosis in patients with chronic liver disease.5 Due to the binding of testosterone to SHBG, the total serum testosterone value can remain normal or occasionally be raised in this patient group, despite reduced levels of free (presumed biologically active) testosterone.6 Therefore, total serum testosterone is not an accurate reflection of sex hormone status in cirrhosis, and free testosterone levels should also be determined in this patient group. Regarding the conclusions of this article suggesting testosterone may be implicated in the pathogenesis of cirrhosis, an alternative explanation of the findings is that total testosterone levels are increased simply as a consequence of elevated SHBG levels, whereas free testosterone levels may actually be reduced. Given higher SHBG levels are seen with worsening fibrosis, this may explain the association, but no definitive conclusions can be made without a full hormone profile. Marie Sinclair M.D.*, Mathis Grossmann M.D. , Paul Gow M.D.*, Peter Angus M.D.*, * Liver Transplantation Unit, Austin Hospital, Heidelberg, Victoria, Australia, Endocrine Unit, Austin Hospital, Heidelberg, Victoria, Australia.
Prevalence of illness, poor mental health and sleep quality and low energy availability prior to the 2016 Summer Olympic Games
Authors: Michael Drew, Nicole Vlahovich, David Hughes, Renee Appaneal, Louise M Burke, Bronwen Lundy, Margot Rogers, Mary Toomey, David Watts, Gregory Lovell, Stephan Praet, Shona L Halson, Candice Colbey, Silvia Manzanero, Marijke Welvaert, Nicholas P West, David B Pyne, Gordon Waddington
Journal: British Journal of Sports Medicine (2017)

Establish the prevalence of illness symptoms, poor sleep quality, poor mental health symptoms, low energy availability and stress-recovery state in an Olympic cohort late in the 3 months prior to the Summer Olympic Games.Olympic athletes (n=317) from 11 sports were invited to complete questionnaires administered 3 months before the Rio 2016 Olympic Games. These questionnaires included the Depression, Anxiety and Stress Questionnaire, Perceived Stress Scale, Dispositional Resilience Scale, Recovery-Stress Questionnaire (REST-Q-52 item), Low Energy Availability in Females Questionnaire (LEAF-Q), Epworth Sleepiness Scale, Pittsburgh Sleep Quality Index and custom-made questionnaires on probiotic usage and travel. Multiple illness (case) definitions were applied. ORs and attributable fractions in the population were used. Factor analyses were used to explore the relationships between variables.The response rate was of 42% (male, n=47, age 25.8±4.1 years; female, n=85, age 24.3±3.9 years). Low energy availability was associated with sustaining an illness in the previous month (upper respiratory, OR=3.8, 95% CI 1.2 to 12). The main factor relating to illness pertained to a combination of anxiety and stress-recovery states (as measured by the REST-Q-52 item). All participants reported at least one episode of illness in the last month (100% prevalence).All participants reported at least one illness symptom in the previous month. Low energy availability was a leading variable associated with illness in Olympic-class athletes. The estimates duration of symptoms ranged from 2 to 7 days. Factor analyses show the interdependence of various health domains and support multidisciplinary care.
Risk, Complexity, Decision Making, and Patient Care
Authors: Rajesh Aggarwal
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Sports Cardiology
Authors: Aaron L. Baggish, Robert W. Battle, James G. Beckerman, Alfred A. Bove, Rachel J. Lampert, Benjamin D. Levine, Mark S. Link, Matthew W. Martinez, Silvana M. Molossi, Jack Salerno, Meagan M. Wasfy, Rory B. Weiner, Michael S. Emery
Journal: Journal of the American College of Cardiology (2017)
Prehospital Blood Transfusion for Combat Casualties
Authors: Eric A. Elster, Jeffrey Bailey
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Potential Use of 18F-THK5351 PET to Identify Wallerian Degeneration of the Pyramidal Tract Caused by Cerebral Infarction
Authors: Kenji Ishibashi, Masashi Kameyama, Tetsuro Tago, Jun Toyohara, Kenji Ishii
Journal: Clinical Nuclear Medicine (2017)

A 41-year-old man underwent F-THK5351 PET 2 years after a right middle cerebral artery infarction. F-THK5351 PET imaging revealed intense radioligand uptake along the ipsilateral pyramidal tract from the corona radiata to the medulla; intense uptake changed from the right side to the left side with descending axial sections at the level of the pyramidal decussation. F-THK5351 reportedly binds to monoamine oxidase B, which is highly expressed in astrocytes, suggesting that F-THK5351 concentrates in the lesion where gliosis occurs. Hence, in this case, F-THK5351 uptake may represent Wallerian degeneration accompanied with gliosis in the ipsilateral pyramidal tract.
Mise en place du Règlement sanitaire international (2005) en Europe
Authors: G Rodier, M Hardiman, B Plotkin, B Ganter
Journal: Eurosurveillance (2006)

L’adoption du Reglement sanitaire international (2005) (egalement reference sous RSI (2005) ou Reglement revise) offre un nouvel et remarquable outil legal pour la protection de la sante publique internationale. Il entrera en vigueur le 15 juin 2007, et l’Article 2 (« Objet et portee ») precise que l’objectif global de l'engagement des Etats Parties (et de l’Organisation Mondiale de la Sante) dans le cadre du Reglement revise sera la prevention, la protection, le controle et la lutte contre la dissemination internationale des maladies, ce par des mesures proportionnees aux risques de sante publique, tout en evitant d’entraver inutilement les echanges internationaux. Les mesures sanitaires prises dans le cadre du Reglement revise seront mises en œuvre dans le respect des droits de l’homme vis-a-vis des voyageurs, ce qui implique plusieurs nouvelles obligations dans ce domaine. Conformement au RSI (2005), les Etats Parties (etats membres de l’OMS qui seront lies par le RSI (2005)) devront posseder des ressources de sante publique dediees a la surveillance et au controle des maladies, ainsi que des ressources supplementaires pour les ports, les aeroports et les postes frontieres internationaux designes. Cet engagement collectif sans precedent necessitera une collaboration etroite entre l’OMS et les Etats Parties, mais egalement une collaboration inter-sectorielle au sein de chaque etat, notamment une cooperation entre les differentes administrations ou niveaux gouvernementaux – un objectif particulierement delicat pour les etats federaux - et transversale entre ministeres et disciplines. La cooperation entre Etats Parties est un aspect cle du Reglement revise, qu’il s’agisse de pays voisins, ou de partenaires commerciaux, des membres d’organisations d’integration economique ou d’autres groupes regionaux, ou simplement des membres de la communaute internationale. Cette collaboration parait particulierement adaptee aux Etats Membres de l’Union Europeenne.
La prévention de la rubéole congénitale dans la région Europe de l'OMS : l'objectif pour 2010
Authors: J. S. Spika, F X Hanon, S Wassilak, R G Pebody, N Emiroglu
Journal: Eurosurveillance (2004)

Le Bureau regional de l'Organisation Mondiale de la Sante (OMS) pour l'Europe a publie recemment un plan strategique et des recommandations pour la surveillance de la rougeole et de la rubeole congenitale. Cette strategie accorde la priorite aux actions visant le controle de la rougeole tout en encourageant l'introduction du vaccin contre la rubeole lorsque la couverture vaccinale de la rougeole est superieure a 90%; cependant, de nombreux pays d'Europe de l'Ouest dont la couverture vaccinale de la rougeole est sub-optimale utilisent deja la vaccin combine rougeole, oreillons, rubeole (ROR). Dans ces pays, les femmes courent un risque particulierement eleve d'avoir un enfant avec une rubeole congenitale. L'objectif de l'OMS est d'ameliorer la surveillance de la rubeole et de la rubeole congenitale afin d'avoir une information fiable quant au poids de ces maladies et de faire prendre conscience aux decisionnaires politiques de la necessite de soutenir la strategie de lutte contre la rubeole du bureau regional de l'OMS pour l'Europe.
Verso una standardizzazione della profilassi post-esposizione anti-HIV per gli operatori sanitari in Europa
Authors: V Puro, S Cicalini, G De Carli, F Soldani, G Ippolito
Journal: Eurosurveillance (2004)

La profilassi antiretrovirale dopo esposizione occupazionale (PPE) ad HIV negli operatori sanitari e ampiamente utilizzata in Europa ma non in modo uniforme. Un gruppo di esperti, in un progetto finanziato dalla Commissione Europea, ha formulato un insieme di raccomandazioni. Quando sulla base delle caratteristiche dell'esposizione sia stata posta l'indicazione all'inizio della PPE, questa dovrebbe essere iniziata il piu presto possibile; l'inizio dopo le 72 ore e sconsigliato. La PPE dovrebbe essere iniziata di routine utilizzando una qualsiasi combinazione di tre antiretrovirali approvata per il trattamento dei pazienti con infezione da HIV; un regime a due classi e preferibile. Per la scelta dei farmaci da combinare, dovrebbe essere indagata la storia farmacologica del paziente fonte. Counselling, supporto psicologico, test per HIV e una valutazione clinica devono essere effettuati a tempo zero, a 6-8 settimane, e almeno 6 mesi dopo l'esposizione. Dovrebbe essere considerato un monitoraggio aggiuntivo clinico e di laboratorio a 1 e 2 settimane, in quanto l'aderenza al regime terapeutico e la sua tollerabilita possono evidenziare reazioni avverse e potenziali tossicita. L'esecuzione routinaria di test di resistenza geno/fenotipica nella fonte e di test per la rilevazione diretta di HIV nell'operatore sanitario e sconsigliata.
Oral Microbiome: A New Biomarker Reservoir for Oral and Oropharyngeal Cancers
Authors: Yenkai Lim, Makrina Totsika, Mark Morrison, Chamindie Punyadeera
Journal: Theranostics (2017)

Current biomarkers (DNA, RNA and protein) for oral cavity and oropharyngeal cancers demonstrate biological variations between individuals, rendering them impractical for clinical translation.Whilst these biomarkers originate from the host, there is not much information in the literature about the influence of oral microbiota on cancer pathogenesis, especially in oral cancers.Oral microbiotas are known to participate in disease initiation and progression not only limited to the oral cavity, but also at other distant sites.Due to the close proximity of oral microbiota and oral cavity and oropharyngeal tumours, abundance changes in oral microbiota may provide useful information on tumourigenesis.This review aims to highlight information on the role of oral microbiota in oral cavity and oropharyngeal cancers.An in-depth analysis into the oral microbiota may provide a new avenue to diagnose and treat these patients.
Temporal trends in the cardiorespiratory fitness of children and adolescents representing 19 high-income and upper middle-income countries between 1981 and 2014
Authors: Grant R Tomkinson, Justin J Lang, Mark S Tremblay
Journal: British Journal of Sports Medicine (2017)

Objective To estimate international and national temporal trends in the cardiorespiratory fitness (CRF) of children and adolescents and to examine relationships between temporal trends in CRF and temporal trends in broad socioeconomic and health-related indicators across countries. Methods Data were obtained from a systematic search of studies that explicitly reported 20 m shuttle run test (a validated measure of CRF) descriptive data on apparently healthy individuals aged 9–17 years. Following the estimation of relative peak oxygen uptake (mL/kg/min) as a measure of CRF, sample-weighted temporal trends were estimated at the country–sex–age level using best-fitting linear or polynomial regression models relating the year of testing to mean CRF. Poststratified population-weighted mean changes in absolute and per cent CRF were estimated. Pearson’s correlations were used to describe the association between linear temporal trends in CRF and linear temporal trends in broad socioeconomic and health-related indicators. Results Temporal trends were estimated from 965 264 children and adolescents from 19 high-income and upper middle-income countries between 1981 and 2014, using data from 137 studies. Collectively, there was a moderate decline in CRF of 3.3 mL/kg/min (95% CI −3.5 to −3.1), equivalent to a decline of 7.3% (95% CI −7.8% to −6.7%) over the 33-year time period. This international decline diminished with each decade and stabilised near zero around 2000. The decline was larger for boys than girls and was similar for children and adolescents. Trends also differed in magnitude and direction between countries, with most showing declines. There was a strong negative association between country-specific trends in income inequality (Gini index) and trends in CRF across 18 countries; meaning, countries approaching income equality had more favourable trends in CRF. Conclusions There has been a substantial decline in CRF since 1981, which is suggestive of a meaningful decline in population health. However, the international trend in CRF has not followed the anticipated trajectory, diminishing and stabilising with negligible change since 2000. CRF data are needed from children in low-income and middle-income countries to more confidently determine true international trends and determine whether temporal trends are similar to those observed in high-income and upper middle-income countries.
Natural killer cells migrate into and control simian immunodeficiency virus replication in lymph node follicles in African green monkeys
Authors: Nicolas Huot, Beatrice Jacquelin, Thalia Garcia-Tellez, Philippe Rascle, Mickaël J Ploquin, Yoann Madec, R Keith Reeves, Nathalie Derreudre-Bosquet, Michaela Müller-Trutwin
Journal: Nature Medicine (2017)
TCT-458 Retrograde CTO PCI of Native Coronary Arteries via Left Internal Mammary Artery Grafts: Insights from a Multicenter US Registry
Authors: Peter Tajti, Dimitri Karmpaliotis, Khaldoon Alaswad, Farouc Amin Jaffer, Robert Yeh, Mitul Patel, Ehtisham Mahmud, James Choi, Nicholas Burke, Anthony Doing, Catalin Toma, Barry Uretsky, Elizabeth Holper, R. Michael Wyman, William Lombardi, David Kandzari, Nicholas Lembo, Santiago Garcia, Oleg Krestyaninov, Dmitrii Khelimskii, Michail Koutouzis, Ioannis Tsiafoutis, Jeffrey Moses, Ajay Jayant Kirtane, Manish Parikh, Ziad Ali, Raja Hatem, Aris Karatasakis, Judit Karacsonyi, Barbara Anna Danek, Bavana Rangan, Emmanouil Brilakis
Journal: Journal of the American College of Cardiology (2017)
Frontline brentuximab vedotin in combination with dacarbazine or bendamustine in patients aged ≥60 years with HL
Authors: Jonathan W. Friedberg, Andres Forero-Torres, Rodolfo E. Bordoni, Vivian J. M. Cline, Dipti Patel Donnelly, Patrick J. Flynn, Gregg Olsen, Robert Chen, Abraham Fong, Yinghui Wang, Christopher A. Yasenchak
Journal: Blood (2017)
Reply
Authors: Morten Lamberts, Gunnar H. Gislason, Jonas Bjerring Olesen, Søren Lund Kristensen, Anne-Marie Schjerning Olsen, Anders Mikkelsen, Christine Benn Christensen, Gregory Y.H. Lip, Lars Køber, Christian Torp-Pedersen, Morten Lock Hansen
Journal: Journal of the American College of Cardiology (2014)